by telrheum | Oct 6, 2024 | Osteoarthritis, Arthritis Supplements, Degenerative Arthritis, Orthopedic
This study explores the use of intra-articular (IA) liraglutide (LIRA), a glucagon-like peptide-1 (GLP-1) analog, for treating osteoarthritis (OA), a common age-related disease that causes chronic pain and restricts mobility. Current treatments, like corticosteroids...
by telrheum | Oct 6, 2024 | Uncategorized
This study investigates the role of B and T cells in kidney biopsies from patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), an autoimmune disease that primarily affects small blood vessels, leading to severe complications in organs...
by telrheum | Sep 29, 2024 | Ankylosing Spondylitis, Biologic Therapy, Spondyloarthritis
The study explored the long-term safety and effectiveness of Bimekizumab (BKZ), a monoclonal antibody designed to block two proteins involved in inflammation, IL-17A and IL-17F. This dual inhibition helps control the excessive inflammation seen in ankylosing...
by telrheum | Sep 28, 2024 | Spondyloarthritis, Acute Phase Reactants, Ankylosing Spondylitis, C-reactive Protein, JAK Inhibitor, Tofacitinib
This article presents a post hoc analysis of how baseline (BL) C-Reactive Protein (CRP) levels affect the efficacy and safety of Tofacitinib, a medication used to treat Ankylosing Spondylitis (AS). Tofacitinib is a Janus kinase inhibitor, a type of drug that helps...
by telrheum | Sep 28, 2024 | Biologic Therapy, Psoriasis, Psoriatic Arthritis
The article reports on the findings from a Phase 2 clinical trial that investigated the effectiveness of Deucravacitinib, a selective Tyrosine Kinase 2 (TYK2) inhibitor, in reducing pain in patients with active Psoriatic Arthritis (PsA). PsA is a chronic inflammatory...